Skip to main content

J. Goldman & Co LP

Position in TRVI — Trevi Therapeutics, Inc.

CIK 1412741 NEW YORK, NY

Position in TRVI

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$2,826,920
-$2,736,429 QoQ
Shares Held
236,959
-46.7% QoQ
Ownership
0.167%
of shares outstanding
% of Portfolio
0.14%
of 13F equity value
Holder Rank
not a current holder
Holding Since
Jun 2022
16 quarters on record
Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in TRVI Over Time

Shares Held

Position Value (USD)

Derivatives in TRVI

reported options exposure · as of Dec 31, 2025
CallValue
$83,884
CallShares
6,700
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

J. Goldman & Co LP holds $186,588,929 across 52 Biotechnology names. TRVI ranks #13 (1.5% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in TRVI

Export CSV
21 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $2,826,920 236,959
2025-12-31 $5,563,349 444,357
2025-12-31 $83,884 6,700
2025-09-30 $7,254,174 792,806
2025-06-30 $5,355,666 979,098
2025-03-31 $1,264,963 201,107
2024-12-31 $3,708 900
2024-12-31 $2,214,949 537,609
2024-12-31 $736,656 178,800
2024-09-30 $3,006 900
2024-09-30 $497,382 148,917
2024-09-30 $411,488 123,200
2024-06-30 $443,772 148,917
2024-03-31 $475,661 137,873
2023-12-31 $184,749 137,873
2023-09-30 $300,563 137,873
2023-06-30 $329,516 137,873
2023-03-31 $164,997 89,188
2022-12-31 $172,132 89,188
2022-09-30 $137,349 89,188
2022-06-30 $379,350 135,000